
|Videos|August 14, 2017
Phase II Results for Cabozantinib in RET-Rearranged Lung Cancer
Author(s)Christine M. Lovly, MD, PhD
Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Tentative Approval to New Cabozantinib Capsule Formulation
2
FDA Clears Rituximab Biosimilar, Expanding Options for B-Cell Malignancies
3
In Squamous NSCLC, Cemiplimab Data Pulled the Room Away From Dual Checkpoint Blockade
4
Real-World Analysis Explores GLP-1 Use and Overall Survival
5










































